

**Systemic Anti Cancer Treatment Protocol**

**Niraparib (maintenance)  
Gynaecological Cancer**

**PROTOCOL REF: MPHANIRMA  
(Version No: 1.4)**

**Due to COVID-19 there has been amendments to approved indications – please refer to Gynae SRG COVID document.**

**Approved for use in:**

- Patients with relapsed, platinum-sensitive and high grade serous ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based SECOND line chemotherapy and who HAVE a germline and/or somatic BRCA mutation
- Patients with relapsed, platinum-sensitive and high grade serous ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based SECOND OR LATER line chemotherapy and who DO NOT HAVE a germline and/or somatic BRCA mutation
- Patients with relapsed, platinum-sensitive and high grade serous ovarian, fallopian tube or primary peritoneal carcinoma who are in response following FIRST line chemotherapy as part of the FOC scheme. Please see alternative protocol for more information.

Treatment needs to start within 8 weeks of completing their previous course of chemotherapy.

Patient must NOT have received previous therapy with a PARP inhibitor unless it has been stopped within 3 months of its start solely as a consequence of toxicity in the absence of disease progression.

**Blueteq registration required: see Blueteq for full eligibility criteria**

Issue Date: 13 <sup>th</sup> November 2020 Review Date: November 2023	Page 1 of 6	Protocol reference: MPHANIRMA
Author: Lauren Williams	Authorised by: Drug & Therapeutics Committee	Version No: 1.4

**Dosage:**

Drug	Dosage	Route	Frequency
Niraparib	300mg	PO	Once daily at night, until disease progression

Treatment will be supplied every 28 days, each capsule contains 100mg.

For patients weighing less than 58kg, a starting dose of 200mg may be considered.

**Supportive treatments:**

Domperidone 10mg oral tablets, up to 3 times a day or as required

**Extravasation risk:**

Not applicable - Oral agent

**Administration:**

Patients can take niraparib with or without food at approximately the same time each day, preferably at night. Capsules must be swallowed whole.

Not to be used in pregnant or breast-feeding women. For patients of child-bearing potential, ensure appropriate contraception is discussed.

**Interactions:**

Niraparib has a minimal likelihood of drug interactions.

Caution is recommended when niraparib is used alongside CYP1A2 metabolised drugs with a narrow therapeutic window (clozapine, theophylline and ropinirole)

Caution is recommended when niraparib is used alongside CYP3A4 metabolised drugs with a narrow therapeutic window (ciclosporin, tacrolimus, alfentanil, ergotamine, pimozide, quetiapine and halofantrine)

Caution is recommended when niraparib is used alongside substrates of BCRP transporters (irinotecan, statins and methotrexate)

**Main Toxicities:**

<b>Niraparib</b>	
Haematological toxicity	Very common - anaemia, neutropenia and thrombocytopenia, leukopenia
Gastrointestinal disorders	Very common- nausea, vomiting, constipation, abdominal pain, mucositis, diarrhea, dyspepsia, dry mouth
General disorders	Very common – fatigue/asthenia, decreased appetite, headache, insomnia, urinary tract infections, rash
Hypertension and tachycardia	Common, but can be managed with anti-hypertensives and dose reduction of niraparib
Embryo-foetal toxicity	Niraparib should not be used during pregnancy and in women of childbearing potential not using reliable contraception during therapy and for 1 month after receiving the last dose of niraparib.
Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML)	Occurred in 0.9% of patients in clinical trials taking Niraparib. Monitor patients for signs of weakness, fatigue, fever, weight loss, infections, bleeding/bruising, breathlessness and haematological toxicities.

**Management of hypertension:**

Treat patients according to the following NICE guidance and refer follow up monitoring and dose adjustment to the GP. <https://www.nice.org.uk/guidance/CG127>

Investigations

	Pre	Cycle 1				Cycle 2				Cycle 3	Cycle 4	Cycle 5	Cycle 6	Ongoing
		D1	D8	D15	D22	D1	D8	D15	D22					
Clinical Assessment	X							X				X		Before cycle 2 and then every 3 cycles thereafter
SACT Assessment	X			X				X		X	X	X	X	Every cycle
FBC	X	X	X	X	X			X		X	X	X	X	Every cycle for the first year then every 3 cycles thereafter
U&E & LFT	X			X				X		X	X	X	X	Every cycle for the first year then every 3 cycles thereafter
CA125	X			X				X		X	X	X	X	Every cycle
Full set of observations (NEWS 2)	X			X				X		X	X	X	X	Every cycle for the first year then every 3 cycles thereafter
BP & HR	X	X	X	X	X	X	X	X	X					Every week for the first 2 months, then every cycle for the first 12 months then every 3 monthly thereafter
CT scan	X													If clinically indicated
Informed Consent	X													
PS recorded	X			X				X		X	X	X	X	Every cycle
Toxicities documented	X			X				X		X	X	X	X	Every cycle
Weight recorded	X			X				X		X	X	X	X	
Height recorded	X			X										

## Dose Modifications and Toxicity Management:

### Haematological toxicities

Proceed with treatment if:-

Hb $\geq$ 80g/L	ANC $\geq$ 1.0 x 10 <sup>9</sup> /L	Platelets $\geq$ 100 x 10 <sup>9</sup> /L
-----------------	-------------------------------------	---

If bloods are:-

Hb < 80g/L	ANC $\leq$ 0.9 x 10 <sup>9</sup> /L	Platelets $\leq$ 99 x 10 <sup>9</sup> /L
------------	-------------------------------------	--

- Recheck FBC weekly.
- Treatment should be discontinued and restarted at a reduced dose when toxicity returns to the thresholds above.
- If delayed for more than 28 days to recover, Niraparib should be discontinued permanently.

### Non-haematological toxicities

Treatment must be interrupted for any patient who experiences an intolerable grade 2 or any grade 3 or 4 adverse event using the CTCAE V3/4, treatment can be restarted at a reduced dose when the toxicity returns to grade 1 or less.

Dose adjustments	
Initial dose	300mg once daily
First dose reduction	200mg once daily
Second dose reduction	100mg* once daily

\*If further dose reduction below 100mg daily is required, discontinue niraparib

**FBC needed weekly for 4 weeks after each dose reduction**

## Renal and hepatic impairment

Renal impairment
Treatment can be administered in patients with mild or moderate renal impairment (creatinine clearance $\geq$ 30 mL/min). There is limited data in patients with severe impairment (creatinine clearance < 30 mL/min) or end stage renal disease undergoing haemodialysis therefore use with caution in these patients

### Hepatic impairment

No dose adjustment is needed in patients with mild or moderate hepatic impairment. There are no data in patients with severe hepatic impairment, use with caution in these patients.

### References

Zejula 100mg hard capsules, Summary of Product Characteristics, Tesaro UK Limited, 16/11/2017. Available from <https://www.medicines.org.uk/emc/product/8828>  
Last updated 04/01/2018

CDF criteria on blueteq forms

Issue Date: 13 <sup>th</sup> November 2020 Review Date: November 2023	Page 6 of 6	Protocol reference: MPHANIRMA
Author: Lauren Williams	Authorised by: Drug & Therapeutics Committee	Version No: 1.4